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Abstract
Prostate cancer is the second most prevalent malignancy in men.
Biomarkers for outcome prediction are urgently needed, so that
high-risk patients could be monitored more closely postopera-
tively. To identify prognostic markers and to determine causal
players in prostate cancer progression, we assessed changes in
chromatin state during tumor development and progression. Based
on this, we assessed genomewide androgen receptor/chromatin
binding and identified a distinct androgen receptor/chromatin
binding profile between primary prostate cancers and tumors with
an acquired resistance to therapy. These differential androgen
receptor/chromatin interactions dictated expression of a distinct
gene signature with strong prognostic potential. Further refine-
ment of the signature provided us with a concise list of nine genes
that hallmark prostate cancer outcome in multiple independent
validation series. In this report, we identified a novel gene expres-
sion signature for prostate cancer outcome through generation of
multilevel genomic data on chromatin accessibility and transcrip-
tional regulation and integration with publically available tran-
scriptomic and clinical datastreams. By combining existing
technologies, we propose a novel pipeline for biomarker discovery
that is easily implementable in other fields of oncology.
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Introduction
Prostate cancer is the second most common cancer in men, with
worldwide more than one million new patients diagnosed and
300,000 deaths annually (Torre et al, 2015). When the disease is con-
fined to the prostate, patients can be treated with prostatectomy and/
or radiotherapy with a curative intent. However, the disease recurs in
30% of patients, for which there is no cure (Amling et al, 2000).
Androgen receptor (AR) plays a pivotal role in prostate cancer
development and progression, by mediating transcription of pro-
mitotic genes, including UBE2C and cyclin D, resulting in prostate
cancer cell proliferation (Xu et al, 2006; Wang et al, 2009). Upon
androgen stimulation, AR dissociates from its chaperones and
translocates to the nucleus (Brinkmann et al, 1999). Subsequently,
AR binds at distinct genomic regions to mediate expression of
directly responsive genes, ultimately leading to tumor cell prolifera-
tion (Itkonen & Mills, 2012). AR binding requires accessible chro-
matin, which is facilitated by pioneer factors, including FOXA1 and
GATA2 (Bohm et al, 2009). Chromatin-bound AR subsequently
recruits coactivators and corepressors which facilitate or repress its
transcriptional activity, respectively (Shang et al, 2002). Differential
expression levels of AR pioneer factors and coregulators correlate
with clinical outcome (Bohm et al, 2009; Sahu et al, 2011), implicat-
ing deregulation of the androgen-signaling axis in prostate cancer
development and progression.
Androgen deprivation therapy (ADT) abrogates androgen signal-
ing either through diminishing androgen synthesis or through
competitive binding of the receptor, both resulting in a reduction of
transcriptional activity of the AR. Patients with failed salvage ther-
apy or metastatic prostate cancer are treated with ADT as a first-line
palliative treatment (Heidenreich et al, 2014a). Moreover, adjuvant
ADT improves the chances of cure for patients treated with
radiotherapy (Pilepich et al, 2001; Bolla et al, 2009). Still, not all
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radiotherapy-treated patients will benefit from adjuvant ADT
(Roach, 2014). After prostatectomy, there is no conclusive evidence
for benefit from adjuvant ADT (Zincke et al, 2001; Dorff et al, 2011;
Miocinovic et al, 2011; Siddiqui et al, 2011; Briganti et al, 2012;
Schubert et al, 2012; Tsurumaki Sato et al, 2014), but it is not unli-
kely that a subgroup of patients may benefit from adjuvant ADT
after prostatectomy. Early identification of high-risk patients would
be of substantial clinical relevance, so that these patients could be
monitored more closely.
D’Amico et al (1998) developed a classification system based on
clinical parameters (PSA, Gleason and clinical staging) to group
men in low, intermediate, and high risk of relapse after therapy with
curative intent. Limitation of this classification is the lack of integra-
tion with multiple risk factors and genomic data, which could
provide more personalized risk assessment. Besides clinical risk
stratifications, a number of different genomic classifications have
been developed that enable the identification of high-risk patients
(Irshad et al, 2013; Lalonde et al, 2014; Ramos-Montoya et al,
2014). However, no such genomic risk assessment biomarkers are
currently adopted in routine clinical practice.
ADT can keep metastatic disease under control for several years,
but practically all tumors eventually develop resistance to treat-
ment. The majority of ADT-resistant tumors maintain active AR
signaling, rendering this pathway a legitimate target for a second-
line endocrine therapy (Valenca et al, 2015). Numerous novel anti-
androgens and androgen depleting agents are being introduced into
the clinic, including enzalutamide (MDV3100), ARN-509, and the
CYP17 inhibitor abiraterone (Potter et al, 1995; Tran et al, 2009;
Clegg et al, 2012). Unlike older anti-androgens (bicalutamide and
flutamide) (Culig et al, 1999; Scher & Sawyers, 2005), the new
generation of anti-androgens (e.g. enzalutamide) prevent nuclear
translocation of AR and do not exhibit agonistic properties. But
despite clinical implementation of these improved inhibitors of AR
signaling, response is partial and temporal and tumors inevitably
progress into a more aggressive and typically lethal form of prostate
cancer (Antonarakis et al, 2014). Various mechanisms underlying
resistance to abiraterone and anti-androgens are known, including
AR overexpression, AR splice variants that confer ligand indepen-
dent AR transactivation, and alterations in expression and recruit-
ment of AR coregulators (Lamb et al, 2014).
AR chromatin binding and expression of AR-responsive genes
were found to deviate between androgen-sensitive and androgen-
resistant cell lines (Wang et al, 2009). Although AR binding profiles
in cell lines have been studied extensively, the genomic behavior of
AR in human prostate specimens remains largely understudied. AR
chromatin binding profiles found in treatment-resistant prostate
tumors were also observed in prostate cancer cell lines, and high-
lighted genes correlated with survival (Sharma et al, 2013).
Recently, AR binding sites were identified that differentiated normal
prostate tissue from cancer, which associated with the onset and
progression of prostate cancer (Chen et al, 2015). Still, no thorough
assessment of AR binding between primary versus resistant tumor
specimens has been performed to date.
By comparing chromatin accessibility (Formaldehyde-Assisted
Isolation of Regulatory Elements (FAIRE)-seq) and AR chromatin
binding profiles (Chromatin Immunoprecipitation (ChIP)-seq) in
primary versus ADT-resistant tumors, we identified a distinct gene
set that enables stratification of patients with prostate cancer on
outcome. With this, our study illustrates that progressive disease
yields prognostic information in primary lesions and provides a
prognostic gene signature to identify patients with prostate cancer at
risk of metastatic relapse after local–regional treatment.
Results
Genomics-based pipeline for biomarker discovery and validation
By combining existing technologies, we here propose a genomics
pipeline for biomarker discovery (Fig 1) and showed its application
in prostate cancer, aimed at identification of prostate cancer patients
with a high-risk of metastatic relapse. Firstly, transcription factor
involvement was identified through motif analysis on open chro-
matin regions. Accessible regions were analyzed to reveal enrich-
ment of a binding motif for a certain transcription factor involved in
disease (prostate cancer). Actual transcription factor binding was
mapped with ChIP-seq to identify sites that are differentially bound
between two sample groups. As a proof-of-principle, we assessed
AR chromatin binding profiles in this study. The target genes of the
differential binding regions were subsequently coupled to gene
expression data in cell lines to uncover genuine involvement of the
transcription factor in expression of a distinct gene set. This gene
set was subsequently tested for association with survival data of
patients, and further refined into a minimal gene signature.
Genomewide profiling of accessible chromatin regions in
prostate tissues by FAIRE-seq
We assessed chromatin accessibility in multiple prostate tissue
specimens as well as the changes thereof in prostate cancer devel-
opment and progression. Four normal prostate tissue samples, four
primary tumors, and three ADT-resistant prostate tumors were
assessed, as well as three prostate cancer metastases (Fig 2A).
FAIRE-seq was applied to identify accessible chromatin regions
with gene-regulatory functions on a genomewide scale (Giresi &
Lieb, 2009). FAIRE is based on phenol–chloroform mediated
sample separation, in which accessible chromatin fragments can be
separated from the condensed state, effectively enriching for regula-
tory genomic regions (schematically visualized in Fig 2A). Metas-
tases and prostate adenocarcinomas contained more than 70%
tumor cells with a Gleason score ranging from 7 (3 + 4) to 10
(5 + 5), while all normal prostate tissues were derived from a
healthy region from prostatectomy specimens. Tumor and normal
tissues were validated by our pathologists. Clinicopathological
parameters are shown in Appendix Table S1. The number of FAIRE
peaks identified was highly variable between the tissues, ranging
from 50 peaks up to over 13,000 peaks (Appendix Table S2).
Figure 2B shows four randomly selected representative coverage
profiles of accessible chromatin at promoter regions. Over 50% of
accessible chromatin sites in healthy and tumor specimens were
found at promoter regions (Fig 2C), and average signal for each
specimen showed clear enrichment of reads at transcription start
sites (Appendix Fig S1). Tumor samples showed more enriched
chromatin accessibility at both intron and distal intergenic regions,
as opposed to normal prostate tissue where FAIRE signal was
mainly found at promoters (Fig 2C).
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The number of sequenced reads as well as called peaks was
lower in normal tissue as compared to any of the tumor samples:
three out of four normal tissue samples (75%) had < 25 million
reads sequenced, while nine out of ten tumor samples had above
25 million reads sequenced (90%; P = 0.04, Fisher’s exact test), and
three out of four normal tissue samples had < 1,000 peaks versus
two out of ten tumor samples (P = 0.09, Fisher’s exact test)
(Appendix Table S2). This suggested presence of more condensed
chromatin in normal prostate tissue compared to tumor. To confirm
this, we compared normalized read count (reads per kilobase per
million (RPKM)) in peaks found in at least three FAIRE-seq samples
(N = 3,010). Read counts were significantly lower in normal tissue
as compared to any of the tumor stages (P < 2.2e16, paired t-test)
(Fig 2D). Normalized read count in advanced disease was lower
than in primary prostate cancer (P < 2.2e16 for both resistant and
metastatic tissue), but still higher than in normal tissue (Fig 2D).
To further focus on the differences in tumorigenesis, we consid-
ered peaks found in at least two out of four normal tissue samples
and two out of four primary tumors. A much larger number of
accessible chromatin regions are found in primary prostate cancer
compared to normal tissue (Fig 2E). This corresponds to a higher
raw signal in primary and other tumor stages compared to normal
tissue (Fig 2F).
To identify transcription factors potentially involved in prostate
cancer development, we performed motif enrichment analysis on
chromatin regions selectively accessible in tumors. In addition, we
analyzed the overlap of accessible FAIRE sites with ChIP-seq data
from a multitude of transcription factors in various cells using the
ReMap annotation tool (Griffon et al, 2015). As expected, multiple
motifs of transcription factors involved in prostate cancer pathobiol-
ogy were found, including ERG (Gasi Tandefelt et al, 2014), AR
(Lonergan & Tindall, 2011), and its pioneer factor FOXA1 (Robinson
& Carroll, 2012) (Table EV1). The motifs are generally conserved
between the individuals (Appendix Table S3). Using the ReMap tool,
we found overlap of FAIRE sites with ChIP-seq signal from a
number of factors from which motifs were found in FAIRE-seq data
(e.g. AR, ERG, SP1, ETS1, and others) (Appendix Fig S2). Moreover,
at these FAIRE regions a weak but statistically significant correlation
was found between motif enrichment and ChIP-seq overlap from
the ReMap tool (Spearman q = 0.30, P = 0.02). CTCF was found to
be an outlier with high score of motif and low degree of overlap,
while AR, MYC, and ERG showed moderate-to-high overlap and
motif score.
Subsequently, mRNA expression and DNA binding for multiple
of these transcription factors were assessed in prostate tumors and
cell lines. For AR, CTCF, ERG, FOXA1, ETV1, and NKX3-1, mRNA
expression was confirmed in four primary tumors (Fig EV1A). Using
publically available ChIP-seq data from LNCaP and VCaP cells, we
could illustrate these factors occupying the FAIRE-seq regions in the
tumors (Fig 2G). As expected, AR binding was enriched at the
enhancer-associated accessible regions, while CTCF occupied both
enhancers and promoters (Taslim et al, 2012). For ERG and CTCF,
we further validated binding at a subset of these regions in
primary tumor specimens by ChIP–qPCR (Fig EV1B–E). Functional
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Figure 1. Genomics-based pipeline for biomarker discovery and validation.
Tissue samples were processed for FAIRE-seq, and transcription factor (TF) motifs in open chromatin regions were analyzed. Selected transcription factor was mapped with
ChIP-seq (in this case androgen receptor) to identify sites that are differentially bound between two sample groups. The target genes of the differential binding regions were
coupled to gene expression and survival data and further refined into a minimal gene signature, which was validated in a number of gene expression datasets.
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involvement of AR was further evidenced by ingenuity pathway
analysis using the list of genes corresponding to the motifs identified
in FAIRE-seq peaks of the primary tumors (Table EV1). This analy-
sis yielded functional networks known to be involved in prostate
cancer, with one network centered around AR (Fig 2H, Appendix
Fig S3).
Distinct genomewide AR binding pattern in primary and resistant
tumors
Since AR and its interactors were enriched at FAIRE-seq regions
(Fig 2G), we next performed AR ChIP-seq on five primary and three
treatment-resistant tumor specimens (Fig 3A). The number of reads
and AR binding events is shown in Appendix Table S4. The total
number of identified AR binding events greatly varied between the
tumor samples (Appendix Table S4), which is consistent with previ-
ous nuclear receptor ChIP-seq in prostate and breast tumor samples
(Ross-Innes et al, 2012; Jansen et al, 2013; Sharma et al, 2013).
Specifically, our AR binding sites varied from 238 up to 17,511 per
tumor sample, which is in the same order of magnitude as in
Sharma et al, with 300–8,500 per tumor sample (Sharma et al,
2013).
Unlike in FAIRE data, the majority (over 90%) of AR ChIP-seq
peaks are present either in intronic or distal intergenic regions
throughout the genome (Figs 2C and 3G), consistent with profiles
identified in cell lines (Yu et al, 2010; Asangani et al, 2014) and
tumors (Sharma et al, 2013). Intra-tumor heterogeneity effect was
limited, as assessed on two independent sections from the same
tumor specimen, with 87% overlap of AR binding sites between the
biological replicates and high correlation of peak read counts
(r = 0.76) (Appendix Fig S4). Overlap of AR ChIP-seq replicates was
comparable to previously described cell line data (Bolton et al,
2007; Jia et al, 2008). AR binding sites selectively enriched in resis-
tant or primary tumors could be observed (Fig 3B), as validated by
AR ChIP–qPCR analyses on additional four primary and five resis-
tant tumors (Fig 3C). Ratios of average enrichment for “resistant
enriched” over “primary tumor enriched” regions were determined,
analogous to what we performed before for breast cancer samples
(Jansen et al, 2013), showing consistent subclassification of patients
in the validation set.
To assess differential AR chromatin binding on a global scale
between treatment-resistant and primary tumors, differential bind-
ing analysis was performed. Peaks present in at least three tumors
(N = 3,138) were considered. In total, 339 genomic regions show
differential AR binding between primary and resistant tumors (for
genomic regions, see Table EV2). Tumors clustered according to
their group identity (primary or resistant) based on these regions
(Fig 3D). Differential AR chromatin binding at these sites is further
evidenced by the difference in average read counts between the
primary and resistant tumors (Fig 3E). To assess the reliability of
differential AR binding events, the samples were shuffled randomly
based on 56 available permutations. Few or no differential peaks
were found when the samples were mislabelled, demonstrating the
robustness of classification and no overfitting (Appendix Fig S5). To
assess whether the identified differential peaks were also relevant in
other clinical datasets, we clustered our data with AR ChIP-seq data
of primary tumors from others (Chen et al, 2015). Three out of four
primary tumors from the other dataset clustered together with the
primary tumors from our study using the 339 identified AR sites
(Fig EV2), suggesting a wider applicability of the differential AR
binding signature.
Differential enriched AR peaks are located mostly in intronic or
distal intergenic regions of the genome (Fig 3F), and primary tumor-
associated AR sites are enriched on chromosomes 16 and 19
(Fig 3G). In contrast, resistance-associated AR binding sites are
enriched on chromosomes 3, 7, and 8, while AR binding at chromo-
somes 6, 12, and 17 is diminished. The peaks remain enriched in
treatment-resistant samples even when the background is subtracted
(Appendix Fig S6).
Motif analysis was performed on all AR binding sites (present in
at least two tumors), resistance-associated AR binding sites and
primary tumor-associated AR sites. As expected, AR binding sites
were enriched for AR motifs, as well as for its pioneer factor FOXA1
(Fig 3H, Appendix Fig S7, Table EV3). Motif enrichment of the AR
coregulator HOXB13 was found selectively in peaks enriched in
resistant tumors (Norris et al, 2009).
Genes proximal to altered AR binding sites are AR-responsive in
sensitive and resistant cell lines
We identified distinct AR binding regions between treatment-resis-
tant and primary prostate tumors. Possible direct target genes were
considered as those with AR binding sites within their body or
20 kb upstream from the transcription start site (Wang et al, 2009),
yielding 158 genes (Table EV4). The limited number of target genes
(158) relative to the 339 AR binding sites can be explained by the
▸Figure 2. Genomewide profiling of chromatin accessibility in prostate cancer specimens.A Overview of the experimental design. Representative examples of H&E-stained slides are shown. DNA and proteins were cross-linked using formaldehyde, followed by
shearing of the chromatin and phenol–chloroform extraction. The organic phase contains compacted DNA (protein–DNA complexes), while DNA recovered from the
aqueous phase represents accessible regulatory regions. DNA from the aqueous phase is further purified and sequenced.
B Snapshots of accessible chromatin regions as assessed through FAIRE-seq in normal prostate tissue (blue), primary tumor (green), treatment-resistant tumor (red),
and metastatic (gray) tissue. Reads are normalized to millions of sequenced reads per sample. Genomic coordinates are indicated.
C Genomic distribution of FAIRE peaks in normal and tumor samples.
D Boxplots depicting normalized FAIRE-seq read counts (RPKM) in different tissues across the peaks found in at least three samples. Read counts in benign tissue (blue)
are lower than in primary tumor (green), therapy-resistant tumor (red) or metastasis (gray) (P < 2.2e16, paired t-test).
E Venn diagram, visualizing shared and unique FAIRE peaks in normal prostate samples (blue) and primary prostate tumor samples (green).
F Heatmap showing raw read count intensity in FAIRE-seq peaks enriched in either normal or tumor samples. The window represents 5 kb around the FAIRE-seq peak.
G Heatmap showing raw read count intensity of ChIP-seq signal from multiple cell line datasets (Appendix Table S12 for references and GEO accession numbers) at
accessible regions identified in primary tumors (peaks present in at least two specimens) ranked on peak intensity. Top panel depicts promoter regions, and the
bottom panel, all other regions. The window represents 5 kb around the FAIRE-seq peak.
H Ingenuity pathway analyses, illustrating one of the networks based on motifs found in FAIRE-seq peaks that were present in at least two out of four primary tumors.
Genes previously described to be involved in prostate cancer are highlighted in blue (other networks in Appendix Fig S3).
◀
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functional involvement of multiple AR binding sites to regulate the
expression of a single gene, as illustrated at the KLK3 locus
(Appendix Fig S8).
Since genes were identified by alterations of AR binding between
primary and resistant tumors, these genes could be AR-responsive in
either an androgen-sensitive or androgen-resistant context. To
dissect these two possibilities, expression of the 158 putative target
genes was explored using a publically available dataset from LNCaP
prostate cancer cells treated for up to 24 h with androgen R1881,
with samples taken every few hours (Fig 4A) (Massie et al, 2011). A
total of 102 genes out of 158 putative AR target genes were found in
the androgen stimulation dataset, represented by 117 expression
probes. In order to group genes according to their temporal profiles,
we clustered the gene expression data using the Short Time-series
Expression Miner (STEM) program. This software utilizes an algo-
rithm that selects potential temporal profiles, assigns genes to those
profiles and computes enrichment significance for each profile (Ernst
et al, 2005; Ernst & Bar-Joseph, 2006). Three significant gene sets
were found: I. upregulated in response to R1881 (41 genes); II. not
affected by R1881 (49 genes); and III. downregulated in response to
R1881 (12 genes) (Fig 4B and C, Table EV5). The 49 genes of gene
set II were of particular interest, since genes not affected by R1881
treatment could still be associated with acquired ADT resistance.
Therefore, expression of these genes was next assessed in a public
gene expression dataset from LNCaP cells cultured in charcoal-
treated hormone-deprived medium for up to 1 year, mimicking
acquired ADT resistance (Fig 4D and E) (D’Antonio et al, 2008). Out
of 49 genes, 48 were annotated in this dataset, corresponding to 164
probes. While not affected by R1881 treatment (Fig 4B and C), these
genes exhibit differential expression during acquisition of ADT resis-
tance (Fig 4E). Expression patterns of gene sets I and III under
androgen deprivation conditions are shown in Appendix Fig S9.
Cumulatively, by integrating our AR ChIP-seq data with publi-
cally available datasets of hormonal response and acquired resis-
tance to ADT, we identified two distinct gene sets associated with
“AR response to hormonal stimuli” and “AR response in acquired
resistance.”
Functional and clinical implications of differential AR-binding-
affected genes
The AR binding landscape in tumors revealed two clearly defined
gene sets, one subset of 53 androgen-responsive genes and the
second subset of 49 acquired ADT resistance genes.
To couple “androgen-responsive” and “acquired resistance”
genes with outcome, gene expression data from 131 primary pros-
tate cancers were analyzed (Taylor et al, 2010). Unsupervised hier-
archical clustering was performed on the 53 “androgen-responsive”
and 49 “acquired resistance” genes separately. The “androgen-
responsive” gene set failed to stratify patients on time to biochemi-
cal (PSA) relapse (P = 0.931, HR = 1.03; 95% CI: 0.47–2.26) (Fig 5A
and B), while clustering on “acquired resistance” genes did stratify
patients (P = 0.032, HR = 0.45; 95% CI: 0.21–0.95) (Fig 5C and D).
Ingenuity pathway analysis illustrated the “androgen-responsive”
genes to be involved mainly in cellular metabolic processes and
correspond to genes normally regulated by steroid hormone recep-
tors AR and PGR (Fig 5E). The “acquired resistance” genes were
additionally involved in androgen biosynthesis and contain genes
related to prostatic carcinoma (Fig 5E).
Refinement and validation of gene expression classifier
We identified a set of 49 “acquired resistance” genes that stratify
patients with prostate cancer on outcome. Since this list is likely to
contain false-positive genes that may jeopardize classification, we
identified a core gene set with a prognostic impact through elastic
net regularization with double-loop cross-validation. Patients were
assigned to two risk groups based on their cross-validated prognos-
tic index (Fig EV3), successfully stratifying patients on time to
relapse (P = 0.00084, log-rank test) (Fig 6A). The refined gene set
classifier is composed of nine genes: DNER, EXT2, AMOTL1,
RBM33, ZBTB20, XBP1, PMFBP1, HSD17B14, and KLF9. Apart from
AR (which was differentially enriched proximal to these genes;
Fig 3), other transcription factors may regulate expression of these
nine prognostic genes as well. Therefore, we investigated the over-
lap of the FAIRE-seq peaks (Fig 2) in close proximity of the nine
genes (< 20 kb from the transcription start site) with a large collec-
tion of public ChIP-seq data from the ReMap tool (Griffon et al,
2015). A strong overlap of the identified eight FAIRE-seq peaks was
found with known players in prostate cancer including AR, FOXA1,
ERG, bromodomains BRD2 and BRD3 and, interestingly, MYC
(Appendix Table S5). The latter also occupies a central place in our
functional motif analysis (Appendix Fig S3).
A prognostic index was assigned to each patient based on the
nine genes, calculated as the sum of expression of the nine genes
multiplied by their corresponding Cox regression coefficients
(Appendix Table S6). This prognostic index is independent from
other known prognostic parameters, such as Gleason score,
▸Figure 3. Distinct AR binding profiles in primary and treatment-resistant tumors.A Overview of experimental design. DNA and proteins were cross-linked using formaldehyde, followed by shearing of the chromatin. Immunoprecipitation for AR was
performed after which isolated DNA fragments were sequenced.
B Snapshots of AR binding events differentially enriched in either primary (green) or resistant (red) tumors. Reads are normalized to millions of sequenced reads per
sample. Genomic coordinates are shown.
C Heatmap illustrating AR ChIP-qPCR validation in independent tumors. Intensity of the color corresponds to ChIP–qPCR enrichment (see scale bar). Binding sites
identified as enriched in either primary or treatment-resistant tumors were tested. Average enrichment in primary tumors was divided over average resistant
enrichment values to determine the ratio, as is visualized in a barplot (bottom panel).
D Differential binding analysis of AR chromatin binding regions, selectively enriched in primary tumors (green) or treatment-resistant (red) tumors.
E Average read counts for AR binding events, selectively enriched between primary (green) or resistant (red) tumors. Data are centered at AR peaks, depicting a 2.5-kb
window around the peak.
F Genomic distributions of AR binding sites shared between tumors or enriched in primary and resistant tumor tissue.
G Distribution of AR binding sites enriched in primary (green) and resistant (red) tumors, by chromosome (%). P-values (one-sided binomial test) for significant
enrichment relative to the entire genome (gray): (a) P = 0.001, (b) P = 0.002, (c) P = 0.003, (d) P = 0.005, (e) P = 9e13, and (f) P = 2.5e13.
H Motif enrichment analysis for AR binding sites shared between tumors or enriched in primary and resistant tumor tissue. Top motifs are shown.
◀
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pathologic T stage, lymph node status, and initial PSA (see
Appendix Table S7 for patient characteristics), and is significantly
associated with time to biochemical recurrence when adjusted for
those known prognostic factors (Appendix Table S8). Furthermore,
we tested the ability of the classifier to identify patients that develop
biochemical recurrence within 5 years after prostatectomy using
receiver operating characteristic (ROC) curves. The area under the
curve (AUC) value for the 9-gene classifier was slightly higher as
compared to an AUC value based on clinical parameters only (0.86
versus 0.83), while combining the genomic classifier with clinical
parameters resulted in an AUC value of 0.9 (Appendix Table S9).
One of the most widely used prostate cancer risk assessment
classification systems was proposed by D’Amico and colleagues
(D’Amico et al, 1998). It utilizes clinical TNM stage, preoperative
PSA level, and biopsy Gleason score to stratify patients in three risk
groups (low-, intermediate-, and high-risk groups). To assess
whether our 9-gene classifier is independent from the D’Amico clas-
sification, we directly compared the output of D’Amico classification
and our 9-gene signature. Low- and high-risk patients as defined by
the genomic signature were found in all three D’Amico risk groups
(Appendix Table S10), and the prognostic potential of our risk group
stratification was independent of D’Amico classification (Appendix
Table S11). Since there was no difference in survival between
D’Amico low- and intermediate-risk groups in patients from Taylor
et al’s cohort (Fig EV4), we combined low- and intermediate-risk
groups together. The 9-gene expression signature was able to further
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stratify patients in both low/intermediate- and high-risk groups
(Fig 6B), which further highlights the utility of our 9-gene signature
on top of existing classification tools.
For validation of the prognostic signature, we used an indepen-
dent gene expression dataset from a cohort of 48 patients with pros-
tate cancer (Boormans et al, 2013). We applied the coefficients from
the trained Cox regression to calculate the prognostic index in the
validation set and successfully stratified patients into two risk
groups with significant difference in time to metastasis (P (log-
rank) = 0.049) (Fig 6C). Furthermore, we examined two other inde-
pendent gene expression clinical studies as well as a set of prostate
cancer xenografts. We used principal component analysis (PCA) to
explore whether expression of the nine genes can separate clinical
groups in these datasets, providing new dimensions (principal
components) that summarize expression of the nine selected genes.
Hormone-sensitive and hormone-refractory tumors and xenografts
are separated along either the first or second principal components
(Fig 6D). With this, we provide evidence that our classifier does not
only stratify patients on biochemical relapse (Fig 6A and B) and
metastasis (Fig 6C), but also successfully makes a distinction
between hormone-refractory and hormone-sensitive tumors (Fig 6D).
Since expression of selected genes is associated with outcome,
similar expression differences may be found in metastatic samples.
Therefore, we examined expression levels of the nine individual
genes in six additional cohorts (Appendix Fig S10, Appendix
Table S12) that include benign (normal), primary, and/or metastatic
prostate cancer samples. Directionality of gene expression in poor-
outcome patients in our discovery set was identical as found in
metastatic samples as compared to primary lesions for all six inde-
pendent cohorts, indicating robustness and consistency (Appendix
Fig S10). These data indicate that potential drivers of poor outcome,
as identified in primary prostate cancers, are possibly preserved in
the metastatic setting.
Discussion
According to current clinical guidelines, endocrine therapy for pros-
tate cancer is prescribed as an adjuvant treatment after radiother-
apy and in the metastatic setting with a palliative intent
(Heidenreich et al, 2014b). The rationale for not applying endo-
crine therapies in the adjuvant management of prostate cancer after
prostatectomy is provided by multiple clinical trials, which illus-
trated limited to no clinical benefit of blocking AR function on
disease-free survival of the entire population (Zincke et al, 2001;
Dorff et al, 2011; Miocinovic et al, 2011; Siddiqui et al, 2011;
Briganti et al, 2012; Schubert et al, 2012; Tsurumaki Sato et al,
2014). Yet, since ~30% of patients with prostate cancer do develop
a relapse later in life, it is believed that a distinct subgroup of
patients may derive benefit from ADT or other subsequent treat-
ment in the adjuvant setting. Above all, patients with high risk
of relapse are in need of closer monitoring postoperatively. To
date, no genomic biomarkers are clinically applied that may aid in
identifying high-risk patients.
Here, we combined existing approaches and technologies
(FAIRE-seq, ChIP-seq, expression analyses, and survival data) as a
potential “genomics pipeline” for biomarker discovery. FAIRE-seq
analyses in prostate cancer specimens led to the identification of a
large set of transcription factor motifs, including AR and multiple of
its interaction partners. As a proof-of-principle, we studied the
genomic behavior of AR. General applicability of such a genomic
pipeline remains to be determined, and future studies should be
aimed at assessing genomic features of other hits from the motif
analyses to illustrate whether this approach is also applicable for
other factors apart from AR.
We illustrate that prognostic biomarkers for the survival of
patients with prostate cancer can be identified through the assess-
ment of AR/chromatin interaction landscapes in tumor samples. By
comparing AR binding patterns in primary tumor tissue specimens
with those found in tumors that have an acquired resistance to treat-
ment, a reprogramming of the AR interactome was observed. This
reprogramming has far-reaching consequences, in which a distinct
and unique gene set with acquired AR-responsive features provides
prognostic potential for the survival of patients with prostate cancer,
independent of classical prognostic parameters and clinical risk
stratification system (D’Amico). Differential AR binding sites were
clearly enriched for specific chromosomes, and a strong enrichment
of resistance-associated AR binding sites was found at chromosome
8. Chromosome 8 has previously been implicated in prostate cancer
progression, containing multiple oncogenes, including Myc (El
Gammal et al, 2010). A selective enrichment of AR binding sites at
distinct chromosomal regions could yield direct biologically relevant
information on prostate cancer progression and may uncover
drivers in ADT resistance.
Since the gene set identified in tumors with an acquired resis-
tance yields prognostic potential in both cohorts of patients with
primary prostate cancer, these data indicate that the AR-driven
processes that were identified in the samples with an acquired resis-
tance may already be active in the primary tumor, driving prostate
tumor progression and metastasis formation. The expression of the
acquired-resistance classifier in primary lesions may be used to
identify patients with high risk of relapse after radical prostatec-
tomy. Identification of high-risk patients is of clear clinical benefit,
since it would enable closer monitoring of these patients. Since our
classifier is based on differences between primary and resistant
tumors, it remains to be determined whether these high-risk patients
would be likely to respond to ADT or would be better treated with
nonhormonal therapeutics.
AR is generally considered as the main driver in prostate
cancer tumorigenesis and tumor progression. This notion is also
further emphasized by the fact that all targeted therapies in pros-
tate cancer treatment are directly aimed in a functional inhibition
of AR activity. Nonetheless, analogous to recent finding in breast
cancer (Robinson et al, 2011; Mohammed et al, 2015), other tran-
scriptional regulators could potentially play a role in prostate
cancer development and progression. AR ChIP-seq differential
binding analysis yielded HOXB13 motif as selectively enriched in
resistant tissue, suggesting a role of HOXB13 in resistant prostate
cancer as found by others (Jeong et al, 2012). In addition, motif
analyses on accessible chromatin regions by FAIRE-seq identified
motifs for a large range of other transcription factors previously
linked to prostate cancer development and progression, including
CTCF, SP1, FOS, and ETS domain family of transcription factors
(Shemshedini et al, 1991; Lu et al, 2000; Taslim et al, 2012;
Chen et al, 2013). A subset of these transcription factors were
previously defined as “druggable,” including ETS family members
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ETV1 (Rahim et al, 2014) and ERG (Nhili et al, 2013) as well as
specific protein (SP) transcription factors (Safe et al, 2014). Out of
the entire nine-gene signature, the three transcription factors
(XBP1, ZBTB20, and KLF9) are previously described in relation to
prostate cancer, while the other genes are not. KLF9 has been
suggested to play a role in the progression of prostate cancer to a
castration-resistant stage (Shen et al, 2014). XBP1 on the other
hand is highly expressed in primary tumor, while hormone-
refractory tumors show weak XBP1 expression (Takahashi et al,
2002; Cuperlovic-Culf et al, 2010). Furthermore, XBP1 is represented
in the 150-core gene set of Sharma et al, while ZBTB20 is found
in the gene set of Chen et al, and both signatures were based on
AR binding in prostate specimens (Sharma et al, 2013; Chen et al,
2015). All these proteins may be of particular interest for new
treatment options in prostate cancer, and future studies are aimed
to further elucidate the potential roles of these transcription
factors in prostate carcinogenesis as well as their therapeutic
potential in this setting.
In summary, using integrative genomics of FAIRE-seq, AR ChIP-
seq, publically available transcriptomic data and patient survival
data, we successfully determined a minimal gene signature for the
outcome of patients with prostate cancer. Even though the prognos-
tic potential of these genes is apparent, future clinical trials should
determine whether these genes could be informative for selective
response to treatment of prostate cancer.
Materials and Methods
Clinical samples
Fresh frozen postoperative prostate needle biopsies from normal
(pathologically validated tumor-free region of the peripheral
zone) and tumor samples were obtained from prostatectomy
specimens at the Netherlands Cancer Institute (Amsterdam, The
Netherlands). The androgen-blockade-resistant tumor samples
[transurethral resection of the prostate (TURP)] and lymph node
metastases were obtained from the Erasmus University Medical
Center (Rotterdam, The Netherlands). The hematoxylin and eosin
(H&E) slides of all these cases were reviewed by our patholo-
gists. See Appendix Table S1 for clinicopathological parameters.
This study was performed in accordance with the Code of
Conduct of the Federation of Medical Scientific Societies in the
Netherlands and has been approved by the local medical ethics
committees.
Formaldehyde-assisted isolation of regulatory elements
FAIRE experiments were performed as previously described (Giresi
& Lieb, 2009). Briefly, fresh frozen tissues were cross-linked with
1% formaldehyde for 20 min. Cells were washed, and nuclei were
isolated as described (Zwart et al, 2013). Subsequently, chromatin
was sonicated and cleared by centrifugation. The soluble chromatin
was subjected to three consecutive phenol–chloroform–isoamyl
alcohol (25:24:1) extractions. The samples were reverse-cross-linked
overnight at 65°C and purified by ethanol precipitation. Purified
samples were treated with RNase A and proteinase K and repurified
by PCR purification kit (Roche).
RNA isolation and mRNA expression
Total RNA was isolated after treatment with RNA-Bee reagent
(Tel-Test, Inc.), and cDNA was synthesized from 500 ng RNA using
SuperScript III Reverse Transcriptase (Invitrogen) with random
hexamer primers. qPCR was performed with SYBR Green (GC
Biotech) on a Roche LightCycler. Primer sequences for mRNA
expression analysis are listed in Appendix Table S13.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitations were performed as described
before (Jansen et al, 2013; Zwart et al, 2013). A total of 10 lg
(ChIP-seq) or 5 lg (ChIP–qPCR) of antibody was used, with 100 ll
(ChIP-seq) or 50 ll (ChIP–qPCR) of Protein A magnetic beads (Invit-
rogen). Antibodies used were AR-N20 (sc-618; Santa Cruz), CTCF
(07-729; Millipore), and ERG (sc-353; Santa Cruz). Primer sequences
for qPCR analysis are in Appendix Table S13.
Solexa sequencing and enrichment analysis
DNA was amplified as described (Jansen et al, 2013). Sequences were
generated by the Illumina HiSeq 2000 Genome Analyzer (using 50-bp
reads) and aligned to the Human Reference Genome (assembly hg19,
February 2009). Reads were filtered based on MAPQ quality: Only
reads with MAPQ above 20 were considered to eliminate reads from
repetitive elements. Enrichment over input control was determined
using DFilter (Kumar et al, 2013) and MACS peak caller version 1.4
(Zhang et al, 2008). Only peaks called by both algorithms were used
for the analysis. MACS was run with the default parameters, except
P = 107 for ChIP-seq data. DFilter was run with bs = 100, ks = 50
for FAIRE data and bs = 50, ks = 30, refine, nonzero for ChIP data.
Read counts, number of aligned reads, and number of peaks are
shown in Appendix Tables S2 (FAIRE) and S4 (ChIP).
The raw and processed data are deposited in the Gene Expression
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/; accession
No. GSE65478).
Data analysis
Motif analyses were performed using Cistrome (cistrome.org),
applying the SeqPos motif tool with default settings (region width:
600 bp; P-value cutoff: 0.001). Genomic distributions of binding
sites were analyzed using the cis-regulatory element annotation
system (CEAS). Differential binding analysis (DBA) was performed
as described (Ross-Innes et al, 2012), considering all peaks that
were found in at least three specimens, without control read
subtraction and using a false discovery rate (FDR) below < 0.10. For
integration with gene expression data, binding events were consid-
ered proximal to the gene when identified in a gene body or within
20 kb upstream from the transcription start site. Publically available
ChIP-seq data for a number of factors in prostate cancer cell lines
were used, and details are summarized in Appendix Table S12.
Expression analyses and survival data
Time-series gene expression was analyzed using Short Time-series
Expression Miner (STEM) (Ernst & Bar-Joseph, 2006) to identify
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gene sets that show significant temporal expression profiles. Default
parameters were used, except for the minimum expression change
set to 0.5 (based on the difference from 0). Two datasets of gene
expression in LNCaP prostate cancer cells were used: GSE18684 and
GSE8702. Details of the publically available gene expression data-
sets that were used in this study (GSE21034, GSE3933, GSE35988,
GSE3325, GSE32269, GSE29079, GSE41408, GSE6811, GSE28680,
GSE21887) are summarized in Appendix Table S12. These datasets
were selected based on the availability of gene expression data from
frozen tissue, relatively large sample sizes, measured on compre-
hensive gene expression platforms and clearly defined clinical
groups. Clinical parameters (where available) of the gene expression
datasets are summarized in Appendix Table S7. Cox regression
regularized by an elastic net penalty from the glmnet package in R
(Friedman et al, 2010) was used in order to select the optimal set of
genes that are significantly associated with survival. Average
centered probe levels were used. Double cross-validation was
performed to assess the overall predictive ability of the procedure.
In the outer loop, leave-one-out cross-validation was used. In the
inner loop, regularization parameter lambda of the elastic net and
the set of active covariates were determined with 10-fold cross-
validation. Then, Cox regression was fitted with the selected variables
and prognostic index estimated for the left-out sample. The final set
of covariates for constructing Cox model was selected based on the
average lambda value. In the validation cohort, prognostic index for
each patient was defined as a sum of gene expression values multi-
plied by their corresponding coefficients derived from the Cox
regression. Patients with prognostic index below or equal to zero
were assigned to the low-risk group, while patients with the prog-
nostic index above zero were assigned to the high-risk group. Dif-
ferences in survival were assessed using log-rank test. Prognostic
index was also used as a covariate in multivariate Cox regression
analysis. The clinical parameters used in the multivariate analyses
included pathologic Gleason score, T stage, lymph node status, and
pretreatment PSA.
Expanded View for this article is available online:
http://emmm.embopress.org
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